Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Francesca Barone sold 13,673 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.22, for a total value of $112,392.06. Following the transaction, the insider now directly owns 124,207 shares of the company's stock, valued at $1,020,981.54. This trade represents a 9.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock traded down $0.55 during trading on Friday, hitting $8.18. 999,637 shares of the stock were exchanged, compared to its average volume of 1,379,625. Candel Therapeutics, Inc. has a 1-year low of $1.16 and a 1-year high of $14.60. The stock has a market capitalization of $265.65 million, a price-to-earnings ratio of -4.73 and a beta of -1.20. The company has a fifty day moving average price of $6.37 and a 200-day moving average price of $6.22. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66.

Institutional Trading of Candel Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth approximately $31,000. FMR LLC acquired a new position in shares of Candel Therapeutics in the third quarter valued at $46,000. MetLife Investment Management LLC bought a new position in shares of Candel Therapeutics in the third quarter valued at about $87,000. Atom Investors LP acquired a new stake in shares of Candel Therapeutics during the 3rd quarter worth about $103,000. Finally, State Street Corp grew its stake in Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company's stock valued at $3,410,000 after buying an additional 19,207 shares during the last quarter. Institutional investors own 13.93% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.